Literature DB >> 11055987

Gene transfer of calcitonin gene-related peptide prevents vasoconstriction after subarachnoid hemorrhage.

K Toyoda, F M Faraci, Y Watanabe, T Ueda, J J Andresen, Y Chu, S Otake, D D Heistad.   

Abstract

We sought to determine whether adenovirus-mediated gene transfer in vivo of calcitonin gene-related peptide (CGRP), a potent vasodilator, ameliorates cerebral vasoconstriction after experimental subarachnoid hemorrhage (SAH). Arterial blood was injected into the cisterna magna of rabbits to mimic SAH 5 days after injection of AdRSVCGRP (8x10(8) pfu), AdRSVbetagal (control virus), or vehicle. After injection of AdRSVCGRP, there was a 400-fold increase in CGRP in cerebrospinal fluid. Contraction of the basilar artery to serotonin in vitro was greater in rabbits after SAH than after injection of artificial cerebrospinal fluid (P<0.001). Contraction to serotonin was less in rabbits with SAH after AdRSVCGRP than after AdRSVbetagal or vehicle (P:<0.02). Basal diameter of the basilar artery before SAH (measured with digital subtraction angiogram) was 13% greater in rabbits treated with AdRSVCGRP than in rabbits treated with vehicle or AdRSVbetagal (P:<0.005). In rabbits treated with vehicle or AdRSVbetagal, arterial diameter after SAH was 25+/-3% smaller than before SAH (P<0.0005). In rabbits treated with AdRSVCGRP, arterial diameter was similar before and after SAH and was reduced by 19+/-3% (P<0.01) after intracisternal injection of CGRP-(8-37) (0.5 nmol/kg), a CGRP(1) receptor antagonist. To determine whether gene transfer of CGRP after SAH may prevent cerebral vasoconstriction, we constructed a virus with a cytomegalovirus (CMV) promoter, which results in rapid expression of the transgene product. Treatment of rabbits with AdCMVCGRP after experimental SAH prevented constriction of the basilar artery 2 days after SAH. Thus, gene transfer of CGRP prevents cerebral vasoconstriction in vivo after experimental SAH.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11055987     DOI: 10.1161/01.res.87.9.818

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  12 in total

Review 1.  The future of gene therapy for stroke.

Authors:  C A Gunnett; D D Heistad
Journal:  Curr Hypertens Rep       Date:  2001-02       Impact factor: 5.369

2.  Impaired vascular responses of insulin-resistant rats after mild subarachnoid hemorrhage.

Authors:  Adam Institoris; James A Snipes; Prasad V Katakam; Ferenc Domoki; Krisztina Boda; Ferenc Bari; David W Busija
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-03-18       Impact factor: 4.733

3.  Receptor activity-modifying protein-1 augments cerebrovascular responses to calcitonin gene-related peptide and inhibits angiotensin II-induced vascular dysfunction.

Authors:  Sophocles Chrissobolis; Zhongming Zhang; Dale A Kinzenbaw; Cynthia M Lynch; Andrew F Russo; Frank M Faraci
Journal:  Stroke       Date:  2010-09-02       Impact factor: 7.914

4.  Age-related neuronal vulnerability to brain ischemia: A potential target of gene therapy.

Authors:  H Ooboshi; S Ibayashi; H Yao; J Takada; D D Heistad; M Fujishima
Journal:  J Am Aging Assoc       Date:  2001-01

Review 5.  Gene therapy for cerebral vascular disease: update 2003.

Authors:  Kazunori Toyoda; Yi Chu; Donald D Heistad
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

6.  The calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS blocks CGRP and adrenomedullin vasoactive responses in the microvasculature.

Authors:  A D Grant; C W Tam; Z Lazar; M K Shih; S D Brain
Journal:  Br J Pharmacol       Date:  2004-07-05       Impact factor: 8.739

7.  Role of calcitonin gene-related peptide in cerebral vasospasm, and as a therapeutic approach to subarachnoid hemorrhage.

Authors:  Stelios Kokkoris; Peter Andrews; David J Webb
Journal:  Front Endocrinol (Lausanne)       Date:  2012-11-15       Impact factor: 5.555

Review 8.  Pathophysiology and therapeutic possibilities of calcitonin gene-related peptide in hypertension.

Authors:  I Márquez-Rodas; F Longo; R P Rothlin; G Balfagón
Journal:  J Physiol Biochem       Date:  2006-03       Impact factor: 5.080

Review 9.  Gene therapy for stroke: 2006 overview.

Authors:  Yi Chu; Jordan D Miller; Donald D Heistad
Journal:  Curr Hypertens Rep       Date:  2007-03       Impact factor: 4.592

10.  Tat peptide-decorated gelatin-siloxane nanoparticles for delivery of CGRP transgene in treatment of cerebral vasospasm.

Authors:  Xin-Hua Tian; Zhi-Gang Wang; Han Meng; Yu-Hua Wang; Wei Feng; Feng Wei; Zhi-Chun Huang; Xiao-Ning Lin; Lei Ren
Journal:  Int J Nanomedicine       Date:  2013-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.